enGene Holdings (ENGN) AI Stock Analysis

• Market Cap: $609.56M
• Dividend Yield: N/A
• Average Volume (3M): 232.96K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.36
• Revenue Growth: N/A
• EPS Growth: -52.86%
• Country: US
• Employees: 56
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.73
• Shares Outstanding: 66,984,660
• 10 Day Avg. Volume: 159,874
• 30 Day Avg. Volume: 232,962
• PEG Ratio: 0.06
• Price to Book (P/B): 2.20
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -3.66
• Enterprise Value/Market Cap: 0.58
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -690.67
• Enterprise Value/Ebitda: -3.09
• 1Y Price Target: $23.75
• Price Target Upside: 157.59% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 8
• EPS Forecast (FY): -2.33
• Revenue Forecast (FY): N/A

• Rating: 55 Neutral
• Price Target: $9.50 ▲(3.04% Upside)

The score is held back primarily by weak financial performance (no revenue, large operating losses, and heavy ongoing cash burn). Technicals provide the main support, with the stock trading above key moving averages and positive MACD. Corporate events are mildly positive due to improved funding and leadership additions, while valuation remains difficult to assess due to a negative P/E and no dividend yield data.

Positive Factors

Regulatory Advancements

Participation in the FDA's pilot program enhances regulatory readiness, potentially accelerating approval timelines and market entry for detalimogene.

Strong Cash Position

A robust cash position ensures operational funding and strategic flexibility, supporting long-term R&D and clinical trial commitments without immediate financial strain.

Leadership Strength

Dr. Sweiti's expertise in oncology and regulatory submissions strengthens enGene's clinical development, enhancing its potential for successful drug approval and commercialization.

Negative Factors

Zero Revenue

The absence of revenue highlights the company's reliance on external funding and underscores the risk until commercial products are developed and approved.

High Operating Losses

Significant operating losses reflect high R&D and operational costs typical of pre-commercial biotech, posing a risk to financial sustainability without revenue generation.

Cash Burn

Persistent negative cash flow indicates ongoing cash burn, necessitating continued external funding and posing a risk to long-term financial stability.

enGene Holdings Business Overview & Revenue Model

Company Description

enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.

How the Company Makes Money

enGene Holdings makes money primarily through the development and commercialization of its gene therapy products. The company's revenue model includes licensing its proprietary technology to pharmaceutical partners, collaborating with research institutions for joint product development, and directly selling its therapeutic products upon regulatory approval. Key revenue streams include milestone payments and royalties from partnerships, as well as potential sales from its own product pipeline. Significant partnerships with established pharmaceutical companies enhance its market reach and contribute to its earnings by accelerating the development and commercialization processes.

enGene Holdings Financial Statement Overview

Summary

enGene Holdings faces significant financial challenges, primarily due to its inability to generate revenue and consistent operational losses. The income statement shows zero revenue and negative profit margins. The balance sheet shows some improvement in equity position, yet it still relies heavily on equity financing. Cash flow statements highlight negative cash flows from operations and free cash flow, indicating the need for capital raising activities. Overall, financial stability requires establishing a revenue stream and improving operational efficiency.

Income Statement

enGene Holdings has consistently reported zero revenue, highlighting a significant challenge in generating sales. The net profit margin is negative due to persistent losses, and the EBIT and EBITDA margins are also deeply negative, reflecting ongoing operational challenges. The absence of revenue growth further emphasizes the critical need for the company to establish a revenue-generating model.

Balance Sheet

The company's debt-to-equity ratio has improved with positive stockholder equity in recent periods, indicating better capital structure management. However, the equity ratio shows a high reliance on equity financing. The persistent losses and negative net income impact the return on equity. Overall, while there is a stable cash position, the company must focus on reducing liabilities to strengthen its balance sheet.

Cash Flow

Operating cash flow remains negative, indicating cash outflows from core operations. However, the company shows strong financing cash flows, suggesting capital raising activities. Free cash flow remains negative, reflecting ongoing operational and capital investment challenges. Improving cash flow from operations is crucial for long-term sustainability.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	-509.00K	-323.00K	-175.00K	0.00	0.00
EBITDA	-113.80M	-52.04M	-94.77M	268.73K	47.00K
Net Income	117.30M	-55.14M	-99.92M	30.73K	-23.44M
Balance Sheet
Total Assets	221.47M	311.17M	86.96M	132.04M	131.45M
Cash, Cash Equivalents and Short-Term Investments	193.81M	238.40M	81.60M	314.15K	1.07M
Total Debt	31.80M	25.02M	9.78M	0.00	0.00
Total Liabilities	53.76M	38.56M	14.47M	4.62M	4.05M
Stockholders Equity	167.71M	272.61M	72.49M	127.42M	127.39M
Cash Flow
Free Cash Flow	-100.72M	-49.21M	-25.06M	-17.75M	-16.23M
Operating Cash Flow	-99.24M	-48.28M	-24.74M	-17.59M	-15.98M
Investing Cash Flow	-25.14M	-125.95M	-318.00K	-153.00K	-247.00K
Financing Cash Flow	1.52M	265.72M	86.15M	27.97M	22.52M

enGene Holdings Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 9.22
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ENGN, the sentiment is Positive. The current price of 9.22 is above the 20-day moving average (MA) of 8.76, above the 50-day MA of 8.12, and above the 200-day MA of 5.62, indicating a bullish trend. The MACD of 0.16 indicates Positive momentum. The RSI at 58.53 is Neutral, neither overbought nor oversold. The STOCH value of 65.86 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ENGN.

enGene Holdings Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CAPR	57 Neutral	$1.35B	―	-107.79%	―	-52.08%	-69.35%
ENGN	55 Neutral	$609.56M	-4.02	-53.28%	―	―	-52.86%
IMRX	52 Neutral	$286.04M	-2.60	-43.75%	―	―	9.32%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
CTNM	50 Neutral	$429.59M	-5.25	-30.40%	―	―	-100.71%
REPL	48 Neutral	$604.80M	-2.02	-96.24%	―	―	-15.77%
TVRD	38 Underperform	$43.44M	-0.46	-97.61%	―	-53.67%	86.75%

enGene Holdings Corporate Events

enGene Holdings Closes $130 Million Public Offering

On November 12, 2025, enGene Holdings Inc. announced the pricing of its public offering of 12,558,823 common shares and pre-funded warrants, expected to raise approximately $130 million. The offering closed on November 14, 2025, and is anticipated to enhance enGene’s financial position, potentially impacting its market presence and stakeholder interests.

The most recent analyst rating on (ENGN) stock is a Buy with a $19.00 price target. To see the full list of analyst forecasts on enGene Holdings stock, see the ENGN Stock Forecast page.